Reply
Tetsuya Hosaka, Fumitaka Suzuki, Hiromitsu Kumada – 7 October 2013
Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor
Alan S. Wang, Ruth M. Pfeiffer, Timothy R. Morgan, Thomas R. O'Brien – 7 October 2013
Individualized treatment for patients with low HCV load (Genotype 1): A viral kinetic approach
Harel Dahari, Scott J. Cotler – 6 October 2013
Early‐onset and late‐onset heart failure after liver transplantation
Odilson M. Silvestre, Alberto Q. Farias, Fernando Bacal – 4 October 2013
“No one really knows why they are alive until they know what they'd die for”: Lessons from the death of a living liver donor
Michael Crawford, Geoffrey McCaughan – 4 October 2013
Hepatitis E infection in liver transplant recipients
Alberto Unzueta, Jorge Rakela – 4 October 2013 – Hepatitis E virus (HEV) infection (genotype 3) has been described in developed countries as a cause of chronic hepatitis in recipients of solid organ transplantation (SOT), with the first cases reported in 2008. Immunosuppression seems to play a major role in the pathogenesis of chronic infections. The current gold standard for the diagnosis of HEV infection is the detection of HEV RNA in serum, stools, or both.
Hemodynamic changes in the hepatic circulation after the modulation of the splenic circulation in an in vivo human experimental model
Nobuhisa Akamatsu, Yasuhiko Sugawara, Shouichi Satou, Tetsuya Mitsui, Riki Ninomiya, Masahiko Komagome, Fumiaki Ozawa, Yoshifumi Beck – 4 October 2013 – Recent advances in liver surgery have highlighted the effects of the splenic circulation on the hepatic circulation with respect to the hepatic arterial buffer response (HABR). The aim of the present study was to investigate the actual hemodynamic effects of splenic artery embolization/ligation and splenectomy on the hepatic circulation in patients who underwent pancreaticoduodenectomy through in vivo experimental models.
Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver
Stefan Wieland, Zuzanna Makowska, Benedetta Campana, Diego Calabrese, Michael T. Dill, Josan Chung, Francis V. Chisari, Markus H. Heim – 3 October 2013 – Approximately 50% of patients with chronic hepatitis C (CHC) have ongoing expression of interferon stimulated genes (ISGs) in the liver. It is unclear why this endogenous antiviral response is inefficient in eradicating the infection. Several viral escape strategies have been identified in vitro, including inhibition of interferon (IFN) induction and ISG messenger RNA (mRNA) translation.
Novel Death Defying Domain in met entraps the active site of caspase‐3 and blocks apoptosis in hepatocytes
Jihong Ma, Chunbin Zou, Lida Guo, Danushka S. Seneviratne, Xinping Tan, Yong‐Kook Kwon, Jiyan An, Robert Bowser, Marie C. DeFrances, Reza Zarnegar – 3 October 2013 – Met, the transmembrane tyrosine kinase receptor for hepatocyte growth factor (HGF), is known to function as a potent antiapoptotic mediator in normal and neoplastic cells. Herein we report that the intracellular cytoplasmic tail of Met has evolved to harbor a tandem pair of caspase‐3 cleavage sites, which bait, trap, and disable the active site of caspase‐3, thereby blocking the execution of apoptosis.
Epigenetic regulation of connective tissue growth factor by MicroRNA‐214 delivery in exosomes from mouse or human hepatic stellate cells
Li Chen, Alyssa Charrier, Yu Zhou, Ruju Chen, Bo Yu, Kitty Agarwal, Hidekazu Tsukamoto, L. James Lee, Michael E. Paulaitis, David R. Brigstock – 3 October 2013 – Connective tissue growth factor (CCN2) drives fibrogenesis in hepatic stellate cells (HSC). Here we show that CCN2 up‐regulation in fibrotic or steatotic livers, or in culture‐activated or ethanol‐treated primary mouse HSC, is associated with a reciprocal down‐regulation of microRNA‐214 (miR‐214).